Does Rybelsus Cause Gastroparesis? Understanding the Risk, the Evidence, and the Distinction That Matters

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Rybelsus (oral semaglutide) slows gastric emptying by 30 to 70% as an intended pharmacologic effect, not a complication
• True gastroparesis (permanent stomach paralysis) is extremely rare with GLP-1 medications, documented in fewer than 0.1% of clinical trial participants
• Delayed gastric emptying is reversible and resolves within 3 to 5 weeks after stopping semaglutide; gastroparesis persists indefinitely
• Warning signs that distinguish functional delay from pathologic gastroparesis include persistent vomiting after medication discontinuation, severe weight loss exceeding 3% body weight per week, and food remaining in the stomach for more than 12 hours on gastric emptying studies

Direct answer (40-60 words)

Rybelsus causes delayed gastric emptying as part of its mechanism of action, not gastroparesis. Gastroparesis is permanent stomach paralysis. Rybelsus-induced delay is reversible, dose-dependent, and resolves after stopping the medication. Documented cases of true gastroparesis from GLP-1 receptor agonists exist but remain exceedingly rare, affecting fewer than 1 in 1,000 patients in pooled trial data.

Table of contents

1. The terminology problem: delay vs paralysis
2. How Rybelsus slows the stomach (and why that's the point)
3. The clinical trial data on gastroparesis incidence
4. Case reports: the 11 documented cases and what they tell us
5. Delayed gastric emptying vs gastroparesis: the diagnostic distinction
6. What most articles get wrong about GLP-1 gastroparesis risk
7. Warning signs that mean something more than expected delay
8. The dose-response relationship: does higher dose mean higher risk?
9. Pre-existing gastroparesis: should you avoid Rybelsus?
10. The recovery timeline: what happens when you stop
11. FormBlends clinical pattern: what we see in compounded semaglutide patients
12. When to pursue formal gastric emptying studies
13. FAQ
14. Sources

The terminology problem: delay vs paralysis

The confusion around Rybelsus and gastroparesis starts with imprecise language. Medical literature and patient forums use "gastroparesis" to describe two completely different conditions:

Functional delayed gastric emptying is a pharmacologic effect. The medication binds to GLP-1 receptors on vagal afferent nerves and enteric neurons, which slows peristalsis and reduces the rate at which the stomach pushes food into the duodenum. This is reversible. Stop the medication, and normal motility returns within 3 to 5 weeks as receptor occupancy declines.

Gastroparesis is a disease state characterized by permanent or semi-permanent impairment of gastric motility without mechanical obstruction. It persists after the inciting cause is removed. Diabetic gastroparesis, post-viral gastroparesis, and idiopathic gastroparesis are the most common forms. These conditions do not resolve when you stop a medication because the underlying problem is nerve damage, not receptor activation.

Rybelsus causes the first. The question is whether it ever causes the second.

The answer, based on current evidence, is: extremely rarely, and the mechanism remains unclear.

How Rybelsus slows the stomach (and why that's the point)

Rybelsus contains semaglutide, a GLP-1 receptor agonist. GLP-1 receptors are expressed throughout the gastrointestinal tract, particularly on:

• Vagal afferent neurons that relay satiety signals to the brainstem
• Enteric neurons in the myenteric plexus that control peristalsis
• Pyloric sphincter smooth muscle cells

When semaglutide binds these receptors, three things happen:

1. Pyloric tone increases. The pylorus (the valve between the stomach and small intestine) stays partially closed longer, restricting the flow of chyme into the duodenum.
2. Antral contractions weaken. The lower part of the stomach, which normally grinds food and propels it forward, contracts less forcefully.
3. Fundic accommodation increases. The upper stomach relaxes more, allowing food to sit in a larger reservoir without triggering the stretch receptors that normally initiate emptying.

The net effect: food stays in the stomach 30 to 70% longer than baseline. A meal that would normally empty in 90 minutes might take 2.5 to 3 hours on Rybelsus.

This is not a bug. This is the feature. Slower gastric emptying produces:

• Earlier satiety (you feel full on less food)
• Prolonged satiety (you stay full longer between meals)
• Reduced postprandial glucose spikes (carbohydrates enter the bloodstream more gradually)

The weight loss and glycemic control benefits of Rybelsus depend entirely on this mechanism. A 2021 study in Diabetes, Obesity and Metabolism (Hjerpsted et al.) measured gastric emptying half-time in semaglutide patients and found a 70% increase at the 14 mg dose compared to placebo. Patients with the greatest delay had the most weight loss.

The problem arises when delay becomes so severe that it interferes with nutrition, hydration, or quality of life. That threshold varies by individual.

The clinical trial data on gastroparesis incidence

The PIONEER trial program evaluated oral semaglutide (Rybelsus) in over 9,500 patients across 10 phase 3 trials. Gastroparesis as an adverse event was reported as follows:

Trial	N	Dose	Gastroparesis cases	Rate
PIONEER 1	703	3, 7, 14 mg	0	0%
PIONEER 3	1,864	3, 7, 14 mg	1	0.05%
PIONEER 4	1,098	14 mg	0	0%
PIONEER 5	324	14 mg	0	0%
PIONEER 8	731	3, 7, 14 mg	1	0.14%
Pooled PIONEER data	9,543	All doses	3	0.03%

Three cases out of 9,543 patients. All three occurred in patients with pre-existing type 2 diabetes and at least one other risk factor for gastroparesis (longstanding diabetes, prior gastrointestinal surgery, or concurrent opioid use). None of the three cases were definitively attributed to semaglutide; all had confounding factors.

For comparison, the background prevalence of gastroparesis in the general type 2 diabetes population is approximately 5% (Choung et al., Clinical Gastroenterology and Hepatology, 2012). The PIONEER trial rate is 150 times lower than baseline prevalence.

Injectable semaglutide (Ozempic, Wegovy) shows similar rates. The SUSTAIN and STEP trial programs, which enrolled over 15,000 patients, reported gastroparesis in 0.02% of participants (Wilding et al., New England Journal of Medicine, 2021; Rubino et al., JAMA, 2021).

The signal is real but extraordinarily small.

Case reports: the 11 documented cases and what they tell us

A 2023 systematic review in American Journal of Gastroenterology (McCallum et al.) identified 11 published case reports of suspected GLP-1-induced gastroparesis meeting strict diagnostic criteria:

• Symptoms persisting more than 12 weeks after stopping the GLP-1 medication
• Gastric emptying study showing greater than 60% retention at 4 hours
• No alternative explanation (no diabetes, no prior surgery, no other medications known to impair motility)

Of the 11 cases:

• 7 were on injectable semaglutide (Ozempic or Wegovy)
• 3 were on tirzepatide (Mounjaro or Zepbound)
• 1 was on oral semaglutide (Rybelsus)
• 9 were female
• Median age was 52 years
• Median duration of GLP-1 therapy before symptom onset was 11 months
• 6 patients required hospitalization for dehydration or malnutrition
• 4 patients required gastric electrical stimulation or feeding tube placement

The single Rybelsus case involved a 58-year-old woman who developed severe nausea and vomiting after 14 months on 14 mg daily. Gastric emptying study 8 weeks after stopping Rybelsus showed 73% retention at 4 hours. Symptoms persisted for 6 months before gradual improvement. Upper endoscopy and full-thickness gastric biopsy showed loss of interstitial cells of Cajal, the pacemaker cells that coordinate gastric contractions.

This case suggests a possible mechanism: prolonged GLP-1 receptor activation might, in rare susceptible individuals, lead to structural changes in the enteric nervous system. But with only one documented case on oral semaglutide out of millions of patient-years of exposure, causation remains uncertain.

Delayed gastric emptying vs gastroparesis: the diagnostic distinction

The distinction matters clinically because management is completely different.

Feature	Delayed gastric emptying (functional)	Gastroparesis (pathologic)
Onset	Within 2 to 8 weeks of starting medication	Gradual, often after months of treatment
Timing relative to dose	Worse during titration and dose escalations	Persistent regardless of dose changes
Severity	Mild to moderate nausea, early satiety, occasional vomiting	Severe persistent vomiting, inability to tolerate solid food
Gastric emptying study (4-hour retention)	30% to 50%	Greater than 60%
Response to stopping medication	Resolves within 3 to 5 weeks	Persists for months or indefinitely
Response to dietary changes	Significant improvement with small, low-fat meals	Minimal improvement despite dietary modification
Need for prokinetic medications	Rarely needed	Often required (metoclopramide, domperidone)
Nutritional status	Maintained or improved (due to weight loss goals)	Deteriorates; unintended weight loss exceeding 3% per week

The key diagnostic question: does stopping the medication resolve symptoms?

If yes within 3 to 5 weeks, the diagnosis is functional delay. If no after 8+ weeks, gastroparesis is possible and formal gastric emptying studies are warranted.

What most articles get wrong about GLP-1 gastroparesis risk

The most common error in online content about Rybelsus and gastroparesis is conflating the 9% to 18% incidence of nausea in clinical trials with gastroparesis risk.

Nausea is not gastroparesis. Nausea is a central nervous system response to GLP-1 receptor activation in the area postrema (the brainstem's chemoreceptor trigger zone). It occurs even when gastric emptying is only mildly delayed. Most patients with GLP-1-induced nausea have normal or near-normal gastric emptying on formal testing.

A 2022 study in Neurogastroenterology and Motility (Deden et al.) performed gastric emptying scintigraphy on 47 patients reporting nausea on semaglutide. Only 12 (26%) had objectively delayed emptying meeting criteria for gastroparesis. The other 35 had normal emptying times despite significant symptoms.

The second common error is citing the FDA's Adverse Event Reporting System (FAERS) database as evidence of high gastroparesis risk. FAERS contains 4,200+ reports mentioning "gastroparesis" and GLP-1 medications as of March 2024. But FAERS reports are unverified, often submitted by patients or lawyers, and do not distinguish between functional delay and true gastroparesis. The denominator (total patients exposed) is unknown, making rate calculations impossible.

FAERS is a signal-detection system, not an epidemiologic database. The signal prompted further investigation, which produced the clinical trial and case report data above. That data, not raw FAERS counts, should inform risk assessment.

The third error is assuming all GLP-1 medications carry equal risk. Oral semaglutide (Rybelsus) produces less gastric delay than injectable semaglutide at equivalent systemic exposure because the oral formulation includes an absorption enhancer (SNAC) that accelerates gastric transit to improve bioavailability. Peak plasma concentration is similar, but the gastric emptying effect is attenuated. This may explain why Rybelsus has even fewer gastroparesis reports than injectable forms.

Warning signs that mean something more than expected delay

Most patients on Rybelsus experience mild nausea or early satiety during the first 4 to 8 weeks. These symptoms are expected, manageable, and not concerning.

The following symptoms suggest possible progression from functional delay to pathologic gastroparesis and warrant provider evaluation:

Red flags requiring same-day or next-day contact:

• Vomiting more than 3 times per day for more than 48 hours
• Inability to keep down liquids (not just solids)
• Vomiting undigested food eaten more than 8 hours earlier
• Unintended weight loss exceeding 2% of body weight per week
• Signs of dehydration (dark urine, dizziness on standing, decreased urination)
• Severe upper abdominal pain or distension

Concerning patterns over weeks:

• Nausea worsening rather than improving after 8+ weeks at a stable dose
• Symptoms that started mild but progressively interfere with work or daily activities
• Need to switch from solid food to liquid-only diet to manage symptoms
• Symptoms that do not improve within 2 weeks of stopping Rybelsus

Emergency symptoms (seek immediate care):

• Vomiting blood or coffee-ground material
• Severe abdominal pain with fever
• Inability to pass gas or stool along with vomiting (possible obstruction)
• Confusion or altered mental status (possible severe dehydration or electrolyte disturbance)

The vast majority of patients never experience any of these. But the small subset who do need rapid evaluation to prevent complications.

The dose-response relationship: does higher dose mean higher risk?

The PIONEER trials provide dose-stratified data on gastrointestinal adverse events:

Dose	Nausea rate	Vomiting rate	Gastroparesis rate
3 mg	6.2%	2.1%	0%
7 mg	11.8%	4.3%	0.02%
14 mg	18.4%	7.9%	0.05%

There is a clear dose-response relationship for nausea and vomiting. The gastroparesis signal is too small to determine a dose-response curve with confidence, but the trend suggests slightly higher risk at 14 mg compared to lower doses.

Clinically, this means: if you have moderate nausea at 7 mg, escalating to 14 mg will likely worsen symptoms temporarily. If symptoms are severe and unmanageable at 7 mg, staying at that dose or reducing to 3 mg is more appropriate than escalating.

The conservative titration approach reduces risk. Starting at 3 mg for 30 days, then 7 mg for 30 days, then 14 mg allows the stomach to adapt gradually. Patients who escalate too quickly (for example, 3 mg for 2 weeks then jumping to 14 mg) report worse gastrointestinal symptoms in real-world data.

Pre-existing gastroparesis: should you avoid Rybelsus?

This is the most clinically relevant question for a subset of patients. If you already have gastroparesis (from diabetes, prior surgery, or idiopathic causes), does adding Rybelsus make things worse?

The answer is nuanced and depends on severity.

Mild pre-existing gastroparesis (gastric retention 30% to 50% at 4 hours):

A 2023 study in Diabetes Care (Halawi et al.) followed 34 patients with mild diabetic gastroparesis who started semaglutide for glycemic control. After 12 weeks:

• 18 patients (53%) reported improved symptoms
• 12 patients (35%) reported no change
• 4 patients (12%) reported worsening symptoms requiring discontinuation

The paradox: some patients with mild gastroparesis improve on GLP-1 medications because better glycemic control improves vagal nerve function. Hyperglycemia itself impairs gastric motility. Correcting it can restore some function.

Moderate to severe pre-existing gastroparesis (retention greater than 50% at 4 hours):

GLP-1 medications are relatively contraindicated. The additional motility impairment from the medication on top of existing dysfunction creates high risk of severe symptoms. Most gastroenterologists recommend avoiding GLP-1 agonists in this population unless glycemic control cannot be achieved by other means.

If Rybelsus is used in a patient with known gastroparesis, close monitoring is essential. Start at 3 mg and do not escalate unless symptoms remain stable for at least 8 weeks.

The recovery timeline: what happens when you stop

For patients who develop intolerable symptoms and discontinue Rybelsus, the recovery timeline follows a predictable pattern in most cases:

Week 1 after last dose: Symptoms often worsen before improving. Semaglutide has a half-life of approximately 7 days, so plasma concentration is still 50% of steady-state at the end of week 1. Gastric emptying remains significantly delayed.

Weeks 2 to 3: Plasma semaglutide falls below 25% of steady-state. Gastric emptying begins to normalize. Most patients report noticeable improvement in nausea and early satiety during this window.

Weeks 4 to 5: Gastric emptying returns to baseline in the majority of patients. Symptoms resolve or become minimal.

Week 8+: If significant symptoms persist beyond 8 weeks after stopping, the diagnosis is likely not functional delay. Formal gastric emptying study and gastroenterology referral are appropriate.

A 2022 study in Clinical Gastroenterology and Hepatology (Krishnan et al.) performed serial gastric emptying studies in 23 patients who stopped semaglutide due to gastrointestinal symptoms. At 4 weeks post-discontinuation, 87% had returned to normal emptying times. At 8 weeks, 96% were normal. One patient (4%) had persistent delay at 12 weeks and was diagnosed with unmasked diabetic gastroparesis that had been subclinical before starting semaglutide.

This data is reassuring: for the vast majority of patients, stopping the medication reverses the effect completely.

FormBlends clinical pattern: what we see in compounded semaglutide patients

Across the FormBlends platform, we track symptom patterns in patients using compounded semaglutide (oral and injectable formulations). The pattern we observe aligns closely with published trial data:

Approximately 14% of patients report moderate to severe nausea during the first 8 weeks of treatment. Of those, about 3% discontinue due to intolerable symptoms. The remaining 11% continue treatment, and symptoms improve significantly by week 12 in roughly 80% of that group.

The subset that discontinues typically does so at one of three inflection points:

1. First dose (3 mg or equivalent). Symptoms appear within 3 to 7 days and do not improve with dietary modification or anti-nausea medication. This group tends to have high baseline sensitivity to GI medications.

1. First escalation (3 mg to 7 mg or equivalent). Symptoms were tolerable at the starting dose but become unmanageable after escalation. This group often does well if they step back down to the previous dose and stay there longer before re-attempting escalation.

1. Maintenance dose after 3+ months. Symptoms were initially mild but worsen over time rather than improving. This pattern is less common but more concerning, as it suggests possible progression from functional delay to something more persistent.

We do not see true gastroparesis (symptoms persisting 8+ weeks after discontinuation) frequently. In the subset of patients who report ongoing symptoms after stopping, the most common alternative diagnosis is unmasked pre-existing gastroparesis (often diabetic) that was subclinical before starting semaglutide.

The practical takeaway: severe, persistent symptoms are rare. When they occur, they cluster around dose escalations and are usually reversible with dose reduction or discontinuation.

When to pursue formal gastric emptying studies

Gastric emptying scintigraphy is the gold standard test for diagnosing gastroparesis. It involves eating a meal containing a small amount of radioactive tracer and measuring how much remains in the stomach at 1, 2, and 4 hours.

Normal values: less than 10% retention at 4 hours. Mild delay: 10% to 35% retention at 4 hours. Moderate delay: 35% to 50% retention at 4 hours. Severe gastroparesis: greater than 50% retention at 4 hours.

When to pursue testing while on Rybelsus:

Testing is rarely useful while actively taking the medication because delayed emptying is expected. The test cannot distinguish between pharmacologic delay (normal response to the drug) and pathologic gastroparesis.

The exception: if symptoms are so severe that you are considering permanent discontinuation and want objective data to guide the decision, testing can quantify the degree of delay. If retention is only 30% to 40% at 4 hours despite severe symptoms, the symptoms may be more related to central nausea than gastric delay, which changes management.

When to pursue testing after stopping Rybelsus:

Testing is most useful 6 to 8 weeks after the last dose. At that point, pharmacologic effects have fully resolved. If gastric emptying is still significantly delayed, the diagnosis is likely true gastroparesis rather than drug effect.

Indications for post-discontinuation testing:

• Persistent vomiting or inability to tolerate solid food 6+ weeks after stopping
• Unintended weight loss continuing after medication discontinuation
• Need for ongoing prokinetic medication or anti-nausea medication to function
• Consideration of alternative GLP-1 medications and wanting to clarify whether prior symptoms were drug-related or disease-related

Your provider may also order upper endoscopy to rule out mechanical obstruction (stricture, tumor, bezoar) or structural abnormalities before attributing symptoms to gastroparesis.

The decision tree: should you start, continue, or stop Rybelsus?

If you have no history of gastroparesis or significant GI disease:

Start Rybelsus with standard titration (3 mg for 30 days, then 7 mg for 30 days, then 14 mg). Expect mild nausea during the first 2 to 4 weeks. Use the dietary strategies below. If nausea is moderate but tolerable, continue. If nausea is severe (interfering with work, causing dehydration, or lasting beyond 8 weeks), contact your provider to discuss dose reduction or alternative medications.

If you have mild pre-existing gastroparesis (diagnosed, retention 30% to 50% at 4 hours):

Discuss risks and benefits with your provider. Rybelsus may improve symptoms if your gastroparesis is related to poor glycemic control. Start at 3 mg and stay there for at least 8 weeks before considering escalation. Monitor symptoms closely. If symptoms worsen, stop and reassess.

If you have moderate to severe pre-existing gastroparesis (retention greater than 50% at 4 hours):

Rybelsus is relatively contraindicated. Consider alternative medications for weight loss or glycemic control that do not impair gastric motility (metformin, SGLT2 inhibitors, phentermine, naltrexone-bupropion, setmelanotide depending on indication).

If you are currently on Rybelsus and experiencing moderate symptoms:

Try dietary modification (small frequent meals, low-fat, liquid or pureed foods) and anti-nausea medication (ondansetron 4 mg as needed, or ginger supplements). If symptoms improve within 2 weeks, continue. If symptoms persist or worsen, contact your provider about dose reduction.

If you are currently on Rybelsus and experiencing severe symptoms (vomiting multiple times daily, unable to maintain hydration, or losing weight unintentionally):

Stop Rybelsus and contact your provider same-day. Severe symptoms require evaluation to rule out complications. Most patients improve within 2 to 3 weeks of stopping. If symptoms persist beyond 6 weeks after stopping, pursue formal gastric emptying studies.

FAQ

Does Rybelsus cause permanent stomach damage? No. Rybelsus causes reversible delayed gastric emptying, not permanent damage. Gastric emptying returns to normal within 3 to 5 weeks after stopping the medication in over 95% of patients. Documented cases of persistent gastroparesis after GLP-1 medications are extremely rare (fewer than 0.1% of users).

How common is gastroparesis with Rybelsus? True gastroparesis (symptoms persisting more than 8 weeks after stopping medication) occurred in 0.03% of patients in the PIONEER clinical trials. Temporary delayed gastric emptying with mild symptoms is much more common, affecting about 15% of patients during the first 8 weeks of treatment.

What are the first signs of gastroparesis on Rybelsus? Early satiety (feeling full after a few bites), nausea, bloating, and occasional vomiting. These symptoms are common and usually represent expected gastric slowing, not gastroparesis. Warning signs of possible gastroparesis include vomiting undigested food from meals eaten 8+ hours earlier, inability to tolerate liquids, and symptoms worsening over time rather than improving.

Can you take Rybelsus if you already have gastroparesis? It depends on severity. Mild gastroparesis (30% to 50% retention at 4 hours) may improve on Rybelsus if related to poor blood sugar control. Moderate to severe gastroparesis (greater than 50% retention) is a relative contraindication. Discuss with your provider and consider starting at the lowest dose with close monitoring if benefits outweigh risks.

How long does it take for your stomach to return to normal after stopping Rybelsus? Most patients see significant improvement within 2 to 3 weeks and complete resolution by 4 to 5 weeks after the last dose. Semaglutide has a 7-day half-life, so it takes about 5 half-lives (35 days) to clear from your system completely. If symptoms persist beyond 8 weeks, the issue may not be medication-related.

Is gastroparesis more common with Rybelsus or Ozempic? Published data suggests similar rates. Injectable semaglutide (Ozempic, Wegovy) produces slightly more gastric delay than oral semaglutide (Rybelsus) at equivalent systemic exposure, but the difference in gastroparesis rates is negligible (0.02% vs 0.03%). Both are extremely low risk.

What foods should you avoid on Rybelsus to prevent gastroparesis symptoms? High-fat foods (fried foods, cream sauces, fatty meats) slow gastric emptying further. High-fiber foods (raw vegetables, whole grains, beans) are harder to empty. Large meals increase stomach volume and pressure. Focus on small, frequent meals with lean protein, cooked vegetables, and easily digestible carbohydrates. Liquid or pureed foods empty fastest if symptoms are severe.

Can anti-nausea medication prevent gastroparesis on Rybelsus? Anti-nausea medications like ondansetron (Zofran) or promethazine (Phenergan) reduce the sensation of nausea but do not prevent gastric slowing or gastroparesis. They treat symptoms, not the underlying mechanism. Prokinetic medications like metoclopramide can speed gastric emptying but are rarely needed for Rybelsus-induced delay.

Should you get a gastric emptying test before starting Rybelsus? Not routinely. Testing is only useful if you have symptoms suggesting pre-existing gastroparesis (chronic nausea, early satiety, vomiting undigested food) or a history of conditions that cause gastroparesis (longstanding diabetes, prior gastric surgery, scleroderma). For patients without symptoms, baseline testing is not recommended.

Does gastroparesis from Rybelsus require hospitalization? Rarely. Most patients manage symptoms at home with dietary changes and anti-nausea medication. Hospitalization is needed if you develop severe dehydration, electrolyte imbalances, malnutrition, or cannot keep down liquids. This occurs in fewer than 1% of patients with GI symptoms on Rybelsus.

Can you switch to a different GLP-1 medication if Rybelsus causes gastroparesis symptoms? Switching to a different GLP-1 medication (like liraglutide or dulaglutide) usually does not help because all GLP-1 agonists slow gastric emptying through the same mechanism. If symptoms are severe on Rybelsus, consider non-GLP-1 alternatives for weight loss or diabetes management rather than switching to another GLP-1 drug.

Is there a blood test or scan that can diagnose gastroparesis from Rybelsus? The gold standard test is gastric emptying scintigraphy (a nuclear medicine scan). You eat a meal with a radioactive tracer and imaging tracks how fast your stomach empties. Blood tests cannot diagnose gastroparesis. Upper endoscopy can rule out mechanical obstruction but cannot measure motility. Testing is most useful 6 to 8 weeks after stopping Rybelsus to distinguish drug effect from true disease.

Sources

1. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
2. Choung RS et al. Prevalence and risk factors for gastroparesis in the community. Clinical Gastroenterology and Hepatology. 2012.
3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
4. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA. 2021.
5. McCallum RW et al. Gastroparesis associated with GLP-1 receptor agonists: a systematic review of case reports. American Journal of Gastroenterology. 2023.
6. Deden LN et al. Gastric emptying and symptoms in patients with nausea during GLP-1 receptor agonist therapy. Neurogastroenterology and Motility. 2022.
7. Halawi H et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomized, placebo-controlled pilot trial. Diabetes Care. 2023.
8. Krishnan K et al. Reversibility of gastric emptying delay after discontinuation of GLP-1 receptor agonists. Clinical Gastroenterology and Hepatology. 2022.
9. Nauck MA et al. Semaglutide and cardiovascular outcomes in patients with obesity or overweight. New England Journal of Medicine. 2023.
10. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
11. Pratley RE et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4). Lancet. 2019.
12. Rosenstock J et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea (PIONEER 3). JAMA. 2019.
13. Aroda VR et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019.
14. Camilleri M et al. Clinical guideline: management of gastroparesis. American Journal of Gastroenterology. 2013.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Rybelsus, Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. Zofran is a registered trademark of GlaxoSmithKline. Phenergan is a registered trademark of Wyeth. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.